drugset
drugset / Trial / NCT00313235

Combined Modality Treatment for Patients With Stage IV Melanoma

NCT00313235 ↗

Phase 1/2 Completed 41 enrolled Baylor Research Institute
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test a combined treatment using cyclophosphamide and a novel dendritic cell vaccine in patients with Stage IV melanoma.

Timeline

Start
2006-03
Primary completion
2011-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 300 mg/m2 Intravenous
Subject DC vaccine Vaccine 1.5e+07 cells Subcutaneous

Indications

melanoma